Louis Chesler
Louis Chesler
UCSF, ICR, RMH
Verified email at icr.ac.uk - Homepage
TitleCited byYear
Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats.
OV Volpert, WF Ward, MW Lingen, L Chesler, DB Solt, MD Johnson, ...
The Journal of clinical investigation 98 (3), 671-679, 1996
3761996
Inhibition of angiogenesis by tissue inhibitor of metalloproteinase
MD Johnson, HRC Kim, L Chesler, G Tsao‐Wu, PJ Polverini, N Bouck
Journal of cellular physiology 160 (1), 194-202, 1994
3211994
Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease.
Y Vodovotz, MS Lucia, KC Flanders, L Chesler, QW Xie, TW Smith, ...
Journal of Experimental Medicine 184 (4), 1425-1433, 1996
3111996
The ALKF1174L mutation potentiates the oncogenic activity of MYCN in neuroblastoma
T Berry, W Luther, N Bhatnagar, Y Jamin, E Poon, T Sanda, D Pei, ...
Cancer cell 22 (1), 117-130, 2012
2062012
Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1
L Chesler, DW Golde, N Bersch, MD Johnson
Blood 86 (12), 4506-4515, 1995
1951995
Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma
L Chesler, C Schlieve, DD Goldenberg, A Kenney, G Kim, A McMillan, ...
Cancer research 66 (16), 8139-8146, 2006
1712006
Regulation of transforming growth factor β1 by nitric oxide
Y Vodovotz, L Chesler, H Chong, SJ Kim, JT Simpson, W DeGraff, ...
Cancer research 59 (9), 2142-2149, 1999
1641999
Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma
M Brockmann, E Poon, T Berry, A Carstensen, HE Deubzer, L Rycak, ...
Cancer cell 24 (1), 75-89, 2013
1562013
Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC
FJ Swartling, V Savov, AI Persson, J Chen, CS Hackett, PA Northcott, ...
Cancer cell 21 (5), 601-613, 2012
1532012
Pleiotropic role for MYCN in medulloblastoma
FJ Swartling, MR Grimmer, CS Hackett, PA Northcott, QW Fan, ...
Genes & development 24 (10), 1059-1072, 2010
1502010
Spontaneously increased production of nitric oxide and aberrant expression of the inducible nitric oxide synthase in vivo in the transforming growth factor beta 1 null mouse.
Y Vodovotz, AG Geiser, L Chesler, JJ Letterio, A Campbell, MS Lucia, ...
Journal of Experimental Medicine 183 (5), 2337-2342, 1996
1261996
Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: a Pediatric Oncology Group study
SL Cohn, AT Look, VV Joshi, T Holbrook, H Salwen, D Chagnovich, ...
Cancer research 55 (4), 721-726, 1995
981995
Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease
RM Hill, S Kuijper, JC Lindsey, K Petrie, EC Schwalbe, K Barker, ...
Cancer cell 27 (1), 72-84, 2015
932015
New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK
G Barone, J Anderson, ADJ Pearson, K Petrie, L Chesler
Clinical Cancer Research 19 (21), 5814-5821, 2013
832013
CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs
MI Walton, PD Eve, A Hayes, MR Valenti, K Alexis, G Box, A Hallsworth, ...
Clinical Cancer Research 18 (20), 5650-5661, 2012
622012
Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction
L Chesler, DD Goldenberg, R Collins, M Grimmer, GE Kim, T Tihan, ...
Neoplasia (New York, NY) 10 (11), 1268, 2008
612008
Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma
L Chesler, DD Goldenberg, IT Seales, R Satchi-Fainaro, M Grimmer, ...
Cancer research 67 (19), 9435-9442, 2007
612007
Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma
NF Moore, AM Azarova, N Bhatnagar, KN Ross, LE Drake, S Frumm, ...
Oncotarget 5 (18), 8737, 2014
562014
The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo
A Faisal, L Vaughan, V Bavetsias, C Sun, B Atrash, S Avery, Y Jamin, ...
Molecular cancer therapeutics 10 (11), 2115-2123, 2011
562011
The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma
G Umapathy, A El Wakil, B Witek, L Chesler, L Danielson, X Deng, ...
Sci. Signal. 7 (349), ra102-ra102, 2014
552014
The system can't perform the operation now. Try again later.
Articles 1–20